Benactyzine

Identification

Name
Benactyzine
Accession Number
DB09023
Type
Small Molecule
Groups
Withdrawn
Description

Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety.

Benactyzine is no longer widely used in medicine, although it is still a useful drug for scientific research. It does not possess any antihistamine properties.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Cedad / Cevanol / Deprol / Lucidil / Morcain / Nutinal / Parasan / Phebex / Phobex / Suavitil (Merck)
Categories
UNII
595EG71R3F
CAS number
302-40-9
Weight
Average: 327.4174
Monoisotopic: 327.183443671
Chemical Formula
C20H25NO3
InChI Key
IVQOFBKHQCTVQV-UHFFFAOYSA-N
InChI
InChI=1S/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 2-hydroxy-2,2-diphenylacetate
SMILES
CCN(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1,10-PhenanthrolineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with 1,10-Phenanthroline.
AclidiniumBenactyzine may increase the anticholinergic activities of Aclidinium.
AgmatineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Agmatine.
AlcuroniumThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alcuronium.
AlfentanilThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alfentanil.
AlimemazineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alimemazine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alphacetylmethadol.
AlphaprodineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Alphaprodine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benactyzine.
AmbenoniumThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Ambenonium.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,394,770.

General References
  1. McLaughlin B, Rickels K, Abidi M, Toro R: Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. Psychosomatics. 1969 Mar-Apr;10(2):73-81. [PubMed:4891208]
External Links
KEGG Drug
D07498
PubChem Compound
9330
PubChem Substance
310264979
ChemSpider
8966
BindingDB
50144504
ChEBI
94775
ChEMBL
CHEMBL70352
Drugs.com
Drugs.com Drug Page
Wikipedia
Benactyzine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)177-178 (Hydrochloride salt)U.S. Patent 2,394,770.
Predicted Properties
PropertyValueSource
Water Solubility0.188 mg/mLALOGPS
logP3.45ALOGPS
logP3.44ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity95.77 m3·mol-1ChemAxon
Polarizability36.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0309000000-31b1e744376b7dab1f25

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Tertiary alcohols / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
Substituents
Diphenylmethane / Tertiary alcohol / Amino acid or derivatives / Carboxylic acid ester / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Alcohol / Aromatic alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on June 25, 2014 11:30 / Updated on August 02, 2018 06:13